What does the future hold for CAR-T? Achieving remission rates of up to 94% in multiple hematologic malignancies…is CAR-T what we’ve been waiting for? Hear from 18+ leading industry speakers about the targeting, commercialization and scalability of CAR-T cell therapy at the CAR-T Congress, 20-22 March 2018, Boston, USA. Join the conversation and impact the future of cell therapy.
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies.
Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
Pick up YOUR copy of this essential resource at CAR-T Congress USA!